肠道微生物能预测联合免疫检查点阻断疗法的疗效和毒性吗？
Can gut microbes predict efficacy and toxicity of combined immune checkpoint blockade?
作者信息
Lam Khiem C, Goldszmid Romina S
机构信息
Inflammatory Cell Dynamics Section, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Inflammatory Cell Dynamics Section, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
出版信息
Cancer Cell. 2021 Oct 11;39(10):1314-1316. doi: 10.1016/j.ccell.2021.09.013.
A recent report in Nature Medicine pinpoints a role for gut microbiota in response and toxicity to combined immune checkpoint blockade targeting CTLA-4 and PD-1. This emergent study provides insights that can be used to leverage microbiota in the design of anticancer therapies to mitigate toxicity while enhancing efficacy.
《自然·医学》最近的一份报告指出，肠道微生物群在针对CTLA-4和PD-1的联合免疫检查点阻断治疗的反应和毒性方面发挥着作用。这项新出现的研究提供了一些见解，可用于在抗癌治疗设计中利用微生物群，以减轻毒性同时提高疗效。
Zotero 插件